Another Win for CRISPR
October 26, 2021 | Terry Sharrer
“Back in 2019 the first CRISPR human clinical trials kicked off in the United States. The trials were aimed at beta-thalassemia and sickle cell disease, two rare blood diseases. The treatment involves harvesting stem cells from a patient’s blood and using CRISPR technology to make a single genetic change designed to raise levels of fetal hemoglobin in red blood cells. . . . Before the CRISPR therapy each of the patients required ongoing blood transfusions, sometimes monthly, but since the infusion every one of them has been transfusion-free. All seven sickle cell patients also showed significant improvement, free of any vaso-occlusive crises, the primary clinical indication of disease.“ MORE
Image Credit: NewAtlas.com